vs
Alector, Inc.（ALEC）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
REPLIGEN CORP的季度营收约是Alector, Inc.的31.7倍（$197.9M vs $6.2M）。REPLIGEN CORP净利率更高（6.7% vs -597.5%，领先604.2%）。REPLIGEN CORP同比增速更快（13.6% vs -88.5%）。过去两年REPLIGEN CORP的营收复合增速更高（14.4% vs -37.4%）
Alector是一家临床阶段生物制药企业，专注于神经退行性疾病的免疫疗法研发，管线覆盖阿尔茨海默病、额颞叶痴呆、帕金森病等未被满足的医疗需求，主要在美国运营，与全球药企合作推进候选药物的临床试验。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
ALEC vs RGEN — 直观对比
营收规模更大
RGEN
是对方的31.7倍
$6.2M
营收增速更快
RGEN
高出102.1%
-88.5%
净利率更高
RGEN
高出604.2%
-597.5%
两年增速更快
RGEN
近两年复合增速
-37.4%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $6.2M | $197.9M |
| 净利润 | $-37.3M | $13.3M |
| 毛利率 | — | 52.5% |
| 营业利润率 | -634.4% | 9.0% |
| 净利率 | -597.5% | 6.7% |
| 营收同比 | -88.5% | 13.6% |
| 净利润同比 | -1696.9% | 143.9% |
| 每股收益（稀释后） | $-0.34 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALECRGEN
| Q4 25 | $6.2M | $197.9M | ||
| Q3 25 | $3.3M | $188.8M | ||
| Q2 25 | $7.9M | $182.4M | ||
| Q1 25 | $3.7M | $169.2M | ||
| Q4 24 | $54.2M | $174.1M | ||
| Q3 24 | $15.3M | $154.9M | ||
| Q2 24 | $15.1M | $154.1M | ||
| Q1 24 | $15.9M | $151.3M |
净利润ALECRGEN
| Q4 25 | $-37.3M | $13.3M | ||
| Q3 25 | $-34.7M | $14.9M | ||
| Q2 25 | $-30.5M | $14.9M | ||
| Q1 25 | $-40.5M | $5.8M | ||
| Q4 24 | $-2.1M | $-30.3M | ||
| Q3 24 | $-42.2M | $-654.0K | ||
| Q2 24 | $-38.7M | $3.3M | ||
| Q1 24 | $-36.1M | $2.1M |
毛利率ALECRGEN
| Q4 25 | — | 52.5% | ||
| Q3 25 | — | 53.2% | ||
| Q2 25 | — | 50.0% | ||
| Q1 25 | — | 53.6% | ||
| Q4 24 | — | 26.1% | ||
| Q3 24 | — | 50.0% | ||
| Q2 24 | — | 49.8% | ||
| Q1 24 | — | 49.5% |
营业利润率ALECRGEN
| Q4 25 | -634.4% | 9.0% | ||
| Q3 25 | -1153.6% | 8.9% | ||
| Q2 25 | -433.6% | 7.6% | ||
| Q1 25 | -1216.5% | 3.9% | ||
| Q4 24 | -13.4% | -17.7% | ||
| Q3 24 | -315.7% | -5.1% | ||
| Q2 24 | -302.4% | 1.0% | ||
| Q1 24 | -275.0% | 1.3% |
净利率ALECRGEN
| Q4 25 | -597.5% | 6.7% | ||
| Q3 25 | -1063.4% | 7.9% | ||
| Q2 25 | -387.7% | 8.2% | ||
| Q1 25 | -1101.6% | 3.4% | ||
| Q4 24 | -3.8% | -17.4% | ||
| Q3 24 | -275.2% | -0.4% | ||
| Q2 24 | -256.4% | 2.2% | ||
| Q1 24 | -227.0% | 1.4% |
每股收益（稀释后）ALECRGEN
| Q4 25 | $-0.34 | $0.24 | ||
| Q3 25 | $-0.34 | $0.26 | ||
| Q2 25 | $-0.30 | $0.26 | ||
| Q1 25 | $-0.41 | $0.10 | ||
| Q4 24 | $-0.02 | $-0.55 | ||
| Q3 24 | $-0.43 | $-0.01 | ||
| Q2 24 | $-0.40 | $0.06 | ||
| Q1 24 | $-0.38 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $256.0M | $767.6M |
| 总债务越低越好 | $10.0M | $542.2M |
| 股东权益账面价值 | $30.6M | $2.1B |
| 总资产 | $293.2M | $2.9B |
| 负债/权益比越低杠杆越低 | 0.33× | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资ALECRGEN
| Q4 25 | $256.0M | $767.6M | ||
| Q3 25 | $291.1M | $748.7M | ||
| Q2 25 | $307.3M | $708.9M | ||
| Q1 25 | $354.6M | $697.2M | ||
| Q4 24 | $413.4M | $757.4M | ||
| Q3 24 | $457.2M | $784.0M | ||
| Q2 24 | $503.3M | $809.1M | ||
| Q1 24 | $562.1M | $780.6M |
总债务ALECRGEN
| Q4 25 | $10.0M | $542.2M | ||
| Q3 25 | — | $537.9M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $10.0M | $525.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ALECRGEN
| Q4 25 | $30.6M | $2.1B | ||
| Q3 25 | $57.7M | $2.1B | ||
| Q2 25 | $71.2M | $2.1B | ||
| Q1 25 | $94.6M | $2.0B | ||
| Q4 24 | $126.8M | $2.0B | ||
| Q3 24 | $118.9M | $2.0B | ||
| Q2 24 | $150.6M | $2.0B | ||
| Q1 24 | $178.9M | $2.0B |
总资产ALECRGEN
| Q4 25 | $293.2M | $2.9B | ||
| Q3 25 | $335.3M | $2.9B | ||
| Q2 25 | $356.4M | $2.9B | ||
| Q1 25 | $408.3M | $2.9B | ||
| Q4 24 | $468.3M | $2.8B | ||
| Q3 24 | $516.0M | $2.8B | ||
| Q2 24 | $570.7M | $2.9B | ||
| Q1 24 | $635.5M | $2.8B |
负债/权益比ALECRGEN
| Q4 25 | 0.33× | 0.26× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.08× | 0.27× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-41.7M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | — | $17.6M |
| 自由现金流率自由现金流/营收 | — | 8.9% |
| 资本支出强度资本支出/营收 | 0.0% | 4.1% |
| 现金转化率经营现金流/净利润 | — | 1.93× |
| 过去12个月自由现金流最近4个季度 | — | $93.9M |
8季度趋势，按日历期对齐
经营现金流ALECRGEN
| Q4 25 | $-41.7M | $25.7M | ||
| Q3 25 | $-32.5M | $48.1M | ||
| Q2 25 | $-49.0M | $28.6M | ||
| Q1 25 | $-60.8M | $15.0M | ||
| Q4 24 | $-55.0M | $39.2M | ||
| Q3 24 | $-50.7M | $49.3M | ||
| Q2 24 | $-62.8M | $42.2M | ||
| Q1 24 | $-61.3M | $44.7M |
自由现金流ALECRGEN
| Q4 25 | — | $17.6M | ||
| Q3 25 | $-32.5M | $43.4M | ||
| Q2 25 | $-49.1M | $21.5M | ||
| Q1 25 | $-60.8M | $11.4M | ||
| Q4 24 | $-55.2M | $33.6M | ||
| Q3 24 | $-50.9M | $42.3M | ||
| Q2 24 | $-63.1M | $37.4M | ||
| Q1 24 | $-61.9M | $36.4M |
自由现金流率ALECRGEN
| Q4 25 | — | 8.9% | ||
| Q3 25 | -997.6% | 23.0% | ||
| Q2 25 | -623.0% | 11.8% | ||
| Q1 25 | -1655.0% | 6.8% | ||
| Q4 24 | -101.8% | 19.3% | ||
| Q3 24 | -332.1% | 27.3% | ||
| Q2 24 | -418.6% | 24.3% | ||
| Q1 24 | -389.3% | 24.0% |
资本支出强度ALECRGEN
| Q4 25 | 0.0% | 4.1% | ||
| Q3 25 | 0.3% | 2.5% | ||
| Q2 25 | 0.1% | 3.9% | ||
| Q1 25 | 0.5% | 2.1% | ||
| Q4 24 | 0.3% | 3.2% | ||
| Q3 24 | 1.4% | 4.5% | ||
| Q2 24 | 2.2% | 3.1% | ||
| Q1 24 | 3.4% | 5.5% |
现金转化率ALECRGEN
| Q4 25 | — | 1.93× | ||
| Q3 25 | — | 3.23× | ||
| Q2 25 | — | 1.92× | ||
| Q1 25 | — | 2.57× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 12.70× | ||
| Q1 24 | — | 21.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
